miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma

8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.

Nat Rev Cancer (2006) 6:259–69. doi: 10.1038/nrc1840

9. Araldi E, Chamorro-Jorganes A, van Solingen C, Fernandez-Hernando

C, Suarez Y. Therapeutic potential of modulating microRNAs in

atherosclerotic vascular disease. Curr Vasc Pharmacol. (2015) 13:291–304.

doi: 10.2174/15701611113119990012

10. Economou EK, Oikonomou E, Siasos G, Papageorgiou N, Tsalamandris S,

Mourouzis K, et al. The role of microRNAs in coronary artery disease: from

pathophysiology to diagnosis and treatment. Atherosclerosis (2015) 241:624–

33. doi: 10.1016/j.atherosclerosis.2015.06.037

11. Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y.

Differential microRNA expression profiling of mesothelioma and expression

analysis of miR-1 and miR-214 in mesothelioma. Int J Oncol. (2016) 48:1599–

607. doi: 10.3892/ijo.2016.3358

12. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D. MicroRNA

(miRNA) transcriptome of mouse retina and identification of a sensory

organ-specific miRNA cluster. J Biol Chem. (2007) 282:25053–66.

doi: 10.1074/jbc.M700501200

13. Li C, Du X, Tai S, Zhong X, Wang Z, Hu Z, et al. GPC1 regulated by miR96-5p, rather than miR-182-5p, in inhibition of pancreatic carcinoma cell

proliferation. Int J Mol Sci. (2014) 15:6314–27. doi: 10.3390/ijms15046314

14. Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, et al. miR-182

integrates apoptosis, growth, and differentiation programs in glioblastoma.

Genes Dev. (2015) 29:732–5. doi: 10.1101/gad.257394.114

15. Li Y, Zhang H, Li Y, Zhao C, Fan Y, Liu J, et al. MiR-182 inhibits the epithelial

to mesenchymal transition and metastasis of lung cancer cells by targeting the

Met gene. Mol Carcinog. (2018) 57:125–36. doi: 10.1002/mc.22741

1. Delgermaa V, Takahashi K, Park E-K, Le G, Hara T, Sorahan T.

Global mesothelioma deaths reported to the World Health Organization

between 1994 and 2008. Bull World Health Organ. (2011) 89:716–24.

doi: 10.2471/BLT.11.086678

2. McDonald JC, McDonald AD. The epidemiology of mesothelioma

in

historical

context.

Eur

Respir

J.

(1996)

9:1932–42.

doi: 10.1183/09031936.96.09091932

3. Milano MT, Zhang H. Malignant pleural mesothelioma: a

population-based study of survival. J Thorac Oncol. (2010) 5:1841–8.

doi: 10.1097/JTO.0b013e3181f1cf2b

4. Kobayashi N, Toyooka S, Yanai H, Soh J, Fujimoto N, Yamamoto

H, et al. Frequent p16 inactivation by homozygous deletion or

methylation is associated with a poor prognosis in Japanese

patients with pleural mesothelioma. Lung Cancer (2008) 62:120–5.

doi: 10.1016/j.lungcan.2008.02.013

5. Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, et al. Survival and

prognostic factors in malignant pleural mesothelioma: a retrospective study

of 314 patients in the west part of Japan. Jpn J Clin Oncol. (2011) 41:32–9.

doi: 10.1093/jjco/hyq159

6. Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, et al.

CD9 expression as a favorable prognostic marker for patients with malignant

mesothelioma. Oncol Rep. (2013) 29:21–8. doi: 10.3892/or.2012.2116

7. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go

a long way. Cell (2009) 136:586–91. doi: 10.1016/j.cell.2009.

02.005

Frontiers in Oncology | www.frontiersin.org

October 2018 | Volume 8 | Article 446

Suzuki et al.

miR-182/183 Expression in Mesothelioma

30. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, MoroSibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma

in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a

randomised, controlled, open-label, phase 3 trial. Lancet (2016) 387:1405–14.

doi: 10.1016/S0140-6736(15)01238-6

31. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P.

MicroRNA therapeutics: discovering novel targets and developing specific

therapy. Perspect Clin Res. (2016) 7:68–74. doi: 10.4103/2229-3485.1

79431

32. Birnie KA, Prêle CM, Thompson PJ, Badrian B, Mutsaers SE.

Targeting microRNA to improve diagnostic and therapeutic approaches

for

malignant

mesothelioma.

Oncotarget

(2017)

8:78193–207.

doi: 10.18632/oncotarget.20409

33. Zhang L, Quan H, Wang S, Li X, Che X. MiR-183 promotes

growth of non-small cell lung cancer cells through FoxO1

inhibition. Tumour Biol. (2015) 36:8121–6. doi: 10.1007/s13277-0153550-8

34. Ichiyama K, Gonzalez-Martin A, Kim BS, Jin HY, Jin W, Xu W,

et al. The microRNA-183-96-182 cluster promotes T helper 17 cell

pathogenicity by negatively regulating transcription factor foxo1

expression. Immunity (2016) 44:1284–98. doi: 10.1016/j.immuni.2016.

05.015

35. Weigel D, Jäckle H. The fork head domain: a novel DNA binding motif of

eukaryotic transcription factors? Cell (1990) 63:455–6.

36. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene (2008)

27:2312–9. doi: 10.1038/onc.2008.24

37. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in

human cancer. Nat Rev Cancer (2002) 2:489–501. doi: 10.1038/nrc839.

38. Hay N. Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta (2011)

1813:1965–70. doi: 10.1016/j.bbamcr.2011.03.013

39. Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, et al. Loss of

FOXO1 Cooperates with TMPRSS2-ERG overexpression to promote

prostate tumorigenesis and cell invasion. Cancer Res. (2017) 77:6524–37.

doi: 10.1158/0008-5472.CAN-17-0686

16. Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X, et al. miR-183 inhibits the

metastasis of osteosarcoma via downregulation of the expression of Ezrin in

F5M2 cells. Int J Mol Med. (2012) 30:1013–20. doi: 10.3892/ijmm.2012.1111

17. Pavlakis E, Tonchev AB, Kaprelyan A, Enchev Y, Stoykova A. Interaction

between transcription factors PAX6/PAX6-5a and specific members of miR183-96-182 cluster, may contribute to glioma progression in glioblastoma cell

lines. Oncol Rep. (2017) 37:1579–92. doi: 10.3892/or.2017.5411

18. Lu, Y. Y., Zheng, J. Y., Liu, J., Huang, C. L., Zhang, W., Zeng, Y. miR183 induces cell proliferation, migration, and invasion by regulating PDCD4

expression in the SW1990 pancreatic cancer cell line. Biomed Pharmacother.

(2015) 70:151–157. doi: 10.1016/j.biopha.2015.01.016

19. Zhao Y, Wang Y, Zhu WG. Applications of post-translational modifications of

FoxO family proteins in biological functions. J Mol Cell Biol. (2011) 3:276–82.

doi: 10.1093/jmcb/mjr013

20. Choi Y, Park J, Ko YS, Kim Y, Pyo JS, Jang BG, et al. FOXO1 reduces

tumorsphere formation capacity and has crosstalk with LGR5 signaling in

gastric cancer cells. Biochem Biophys Res Commun. (2017) 493:1349–55.

doi: 10.1016/j.bbrc.2017.09.163

21. Zhao Z, Qin L, Li S. miR-411 contributes the cell proliferation of

lung cancer by targeting FOXO1. Tumour Biol. (2016) 37:5551–60.

doi: 10.1007/s13277-015-4425-8

22. He W, Feng L, Xia D, Han N. MiR-374a promotes the proliferation of human

osteosarcoma by downregulating FOXO1 expression. Int J Clin Exp Med.

(2015) 8:3482–9.

23. Song W, Wang L, Li Q. Interplay of miR-21 and FoxO1 modulates

growth of pancreatic ductal adenocarcinoma. Tumour Biol. (2015) 36:4741–5.

doi: 10.1007/s13277-015-3123-x

24. Chen J, Huang Q, Wang F. Inhibition of FoxO1 nuclear exclusion

prevents metastasis of glioblastoma. Tumour Biol. (2014) 35:7195–200.

doi: 10.1007/s13277-014-1913-1

25. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, et al.

Definition of microRNAs that repress expression of the tumor suppressor

gene FOXO1 in endometrial cancer. Cancer Res. (2010) 70:367–77.

doi: 10.1158/0008-5472.CAN-09-1891

26. Lamprecht MR, Sabatini DM, Carpenter AE. CellProfiler: free, versatile

software for automated biological image analysis. Biotechniques (2007) 42:71–

5. doi: 10.2144/000112257

27. Gebäck T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and

simple software tool for automated analysis of monolayer wound healing

assays. Biotechniques (2009) 46:265–74. doi: 10.2144/000113083

28. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR96, and miR-182 in breast cancer cells. J Biol Chem. (2009) 284:23204–16.

doi: 10.1074/jbc.M109.031427

29. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, et al.

Survival of pleural malignant mesothelioma in Italy: a population-based study.

Int J Cancer (2009) 124:201–7. doi: 10.1002/ijc.23874

Frontiers in Oncology | www.frontiersin.org

Conflict of Interest Statement: The authors declare that the research was

conducted in the absence of any commercial or financial relationships that could

be construed as a potential conflict of interest.

Copyright © 2018 Suzuki, Amatya, Kushitani, Kai, Kambara and Takeshima. This

is an open-access article distributed under the terms of the Creative Commons

Attribution License (CC BY). The use, distribution or reproduction in other forums

is permitted, provided the original author(s) and the copyright owner(s) are credited

and that the original publication in this journal is cited, in accordance with accepted

academic practice. No use, distribution or reproduction is permitted which does not

comply with these terms.

October 2018 | Volume 8 | Article 446

...